Logo

PharmaShots Weekly Snapshots (September 09 – September 13, 2024)

Share this

PharmaShots Weekly Snapshots (September 09 – September 13, 2024)

This week PharmaShots’ news was all about the updates on Clinical Trials, Pharma, Biotech, COVID-19, Regulatory & MedTech. Check out our full report below:

 

Merck & Daiichi Sankyo Report the P-II (IDeate-Lung01) Study Data of Ifinatamab Deruxtecan to Treat Extensive-Stage Small Cell Lung Cancer

Read More: Merck & Daiichi Sankyo                                                                          

Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC

Read More: Johnson & Johnson                                                                       

Savara Highlights New P-III (IMPALA-2) Study Data of Molgramostim to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at ERS 2024

Read More: Savara                                                                                                       

Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

Read More: Akeso                                                                                                        

GSK Highlights Full Results from the P-III (SWIFT-1 and SWIFT-2) Trials of Depemokimab for Treating Severe Asthma at ERS 2024

Read More: GSK                                                                                                             

Phanes Therapeutics Reports the First Patient Dosing with PT886 in P-I/II Study for Pancreatic and Gastric Cancer

Read More: Phanes Therapeutics                                                                             

AstraZeneca & Daiichi Sankyo Highlight the P-III (TROPION-Lung01) Study Data of Datopotamab Deruxtecan (Dato-DXd) to Treat Non-Squamous NSCLC at WCLC 2024

Read More: AstraZeneca & Daiichi Sankyo                                                               

Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024

Read More: Bayer                                                                                                   

Eli Lilly Reports Detailed Results from the P-III (QWINT-2 & 5) Trials of Insulin Efsitora Alfa (Efsitora) for Type 1 & 2 Diabetes at EASD 2024

Read More: Eli Lilly                                                                                                 

GSK Reports P-I/II Study Updates of GSK3943104 HSV Vaccine

Read More: GSK                                                                                                          

Sanofi Reports the P-III (LIBERTY-CUPID Study C) Trial Data of Dupixent to Treat Chronic Spontaneous Urticaria (CSU)

Read More: Sanofi                                                                                                          

Bayer Reports the P-III (OASIS 3) Trial Data of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women

Read More: Bayer                                                                                                   

GSK Reports Headline Data from P-II Study of Seasonal Influenza mRNA Vaccine

Read More: GSK                                                                                                            

Merck Reports Top-line Data from the P-III (V503-064) Study of Gardasil 9 in Japanese Males

Read More: Merck                                                                                                

Neurocrine Biosciences Provides P-II (ERUDITE) Study Updates of Luvadaxistat for Cognitive Impairment Associated with Schizophrenia

Read More: Neurocrine Biosciences                                                                       

 

Cartesian Therapeutics’ Descartes-08 Gains the US FDA’s Rare Pediatric Disease Designation to Treat Juvenile Dermatomyositis

Read More: Cartesian Therapeutics                                                                          

BridgeBio’s BBP-812 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for Canavan Disease

Read More: BridgeBio                                                                                                 

Johnson & Johnson Reports the US FDA’s Approval of Tremfya to Treat Ulcerative Colitis

Read More: Johnson & Johnson                                                                             

Neuraptive Therapeutics’ NTX-001 Gains the US FDA’s Breakthrough Therapy Designation to Treat Peripheral Nerve Injury Requiring Repair

Read More: Neuraptive Therapeutics                                                               

Roche’s Tecentriq Hybreza Receives the US FDA’s Approval for Cancer Treatment

Read More: Roche                                                                                                      

GSK’s Blenrep Combination Gains the NMPA’s Breakthrough Therapy Designation to Treat R/R Multiple Myeloma

Read More: GSK                                                                                                        

Merck reports the Health Canada’s Approval of Keytruda to Treat MSI-H or dMMR Solid Tumors

Read More: Merck                                                                                                        

 

Circle Pharma Features Preclinical Results of CID-078 at the WCLC 2024

Read More: Circle Pharma                                                                                         

Scientist.com Collaborates with Evotec to Expedite Drug Discovery and Development

Read More: Scientist.com & Evotec                                                                 

 

Enigma Biomedical - USA Partners with Alamar Biosciences to Advance the Diagnostics for Neurodegenerative Diseases

Read More: Enigma Biomedical & Alamar Biosciences                                      

Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine

Read More: Alopexx & Bharat Biotech                                                                    

Sanofi, RadioMedix and Orano Med Join Forces to Develop AlphaMedix (212Pb-Dotamtate) for Rare Cancer Treatment

Read More: Sanofi, RadioMedix & Orano Med                                                 

ITM Isotope Technologies Munich and Debiopharm Partner to Develop ITM-91/ITM-94D Theranostic Pair for Solid Tumors

Read More: ITM Isotope Technologies Munich & Debiopharm                    

Marengo Therapeutics Partners with Gilead to Conduct Clinical Trial of Invikafusp alfa Plus Trodelvy for Metastatic TNBC and Breast Cancers

Read More: Marengo Therapeutics & Gilead                                                    

 

Alex Therapeutics and Navamedic Collaborate to Develop a Companion App for Parkinson’s Disease

Read More: Alex Therapeutics & Navamedic                                                        

Related Post: PharmaShots Weekly Snapshots (September 02 – September 06, 2024)


Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions